

Purdue Research Park
3000 Kent Avenue, Suite C1-100
West Lafayette, IN 47906-1075

(765) 464-8414 (General)
(765) 464-8408 (Fax)

March 30, 2020

RE: COVID-19 Pandemic Preparedness and Operations

Dear Clients, Partners, and Suppliers:

First, we, at Parsolex, hope that you and your family, friends, and colleagues are safe and healthy. Second, we want to thank you for continued support, confidence, and partnership.

We acknowledge that everyone is operating in a time of global uncertainty owing to the novel coronavirus, COVID-19, pandemic. That said, we, at Parsolex, are sad for all the loss and heartache occurring around the world at the moment. Fortunately, we believe that by working together as a single global community, we can and will overcome this crisis and its impact on our connected global society. Therefore, we want to communicate our initiatives with respect to combating the COVID-19 pandemic:

Essential Business and Operations

Since Gov. Holcomb's authorization of Executive Order 20-08 (Directive for Hoosiers to Stay at Home) in the State of Indiana on 24 March 2020, we have declared ourselves a company operating under the definition of "Essential Business and Operations," enabling us to continue our efforts to provide solutions to not only the pharmaceutical industry but now also our global community in general during the effective duration of this state-government mandate. Therefore, we remain open for business, as we have done so since 2005 when the company first started our commercial operations.

Our Team's Health and Safety

As called out in Gov. Holcomb's Executive Order, we have equipped our entire team with the ability to work from home as often as possible, asking individual team members to work on site if and when needed. Furthermore, we have provided guidance to our entire team on when to work from home, when to work at our site, and when to return to work (at our site) after recovering from illness, in addition to provided education on both good hygiene and "social distancing" practices. We have also implemented procedures to make sure that each visitor, whether from a client, partner, or supplier, to our site is evaluated for COVID-19 infection risk prior to receiving permission to enter our facilities. Clearly, our team is core to our operations, and we want to make sure that each team member is healthy and safe.

Our Operations and Commitments

While we currently operate with a minimal amount of team members at our site as guided by Gov. Holcomb's Executive Order and current operating guidelines (e.g., Centers for Disease Control and Prevention, or the "CDC"), we continue our operations, delivering on our commitments to our clients and partners. Admittedly, we have been working on securing our supply chain since the beginning of this year. We have been procuring materials and supplies to make sure that we have ample inventories to deliver against on our existing commitments and, if appropriate, on new commitments. Furthermore, we have been in discussion with our partners and suppliers to understand their operations and evaluating the need to expand our network of partners and suppliers to supplement our operations. Please take comfort to know that we are on your side, we remain supportive of your efforts, we can be flexible as needed and appropriate, and we are placing our best efforts possible to assist you, despite any uncertainties, distractions, and/or hinderances that we may be facing together.

Our Social Responsibility

We operate the only pharmaceutical manufacturing site approved by the U.S. Food & Drug Administration ("FDA") to produce Seromycin™ (Cycloserine Capsules, 250 mg), which is indicated for the treatment of multiple-drug resistant tuberculosis ("MDR-TB") and urinary tract infection ("UTI")ⁱ. We acknowledge this fact, and, as our social responsibility, we are committed to maintaining the supply of this therapy to minimize the risk for this patient population and for additional burden from a public health perspective.

Our Capital Investment Program

As you may know, we launched a Capital Investment Program in 2019 to expand our capabilities and enhance our operations to serve our clients and partners better. Despite the current uncertainties, we remain focused and plan to complete our investment efforts. We are excited to complete this program, and we hope that these additional capabilities will be available and of benefit to you, if needed, during these uncertain times. That said, we look forward to sharing information with you about the results of our investments upon the completion of this program. For now, a preview of this efforts can be found in a recent article published by [Tablets & Capsules](#).

We hope that the above words provide you with some comfort and with at least one item that you do not need to address — your partnership with Parsalex — in these uncertain times. We understand that you may have enough to do, address, and take care of at the moment. Please stay healthy and safe.

Please let us know how we can help, as we are here to do so. Your successes define our successes. Therefore, we thank you for your trust, confidence, and partnership. We are here to offer you solutions and excellence.

Best wishes,

Alfonso Chang
President / CEO

ⁱ Parsalex does not advocate or promote off label uses of Seromycin™ (Cycloserine Capsules, 250 mg). Additional details on the drug can be found on the [package insert](#).